Top

Radiation Oncology

Published in:

Open Access 01-12-2010 | Research

RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab

Authors: Alexandra D Jensen, Jürgen Krauss, Wilko Weichert, Jürgen Debus, Marc W Münter

Published in: Radiation Oncology | Issue 1/2010

Abstract

Background

Local control in adjuvant/definitive RT of adenoid cystic carcinoma (ACC) is largely dose-dependent. However, some clinical situations do not allow application of tumouricidal doses (i.e. re-irradiation) hence radiation sensitization by exploitation of high endothelial growth factor receptor (EGFR)-expression in ACC seems beneficial. This is a single-institution experience of combined radioimmunotherapy (RIT) with the EGFR-inhibitor cetuximab.

Methods

Between 2006 and 2010, 9 pts received RIT for advanced/recurrent ACC, 5/9 pts as re-irradiation. Baseline characteristics as well as treatment parameters were retrieved to evaluate efficacy and toxicity of the combination regimen were evaluated. Control rates (local/distant) and overall survival were calculated using Kaplan-Meier estimation.

Results

Median dose was 65 Gy, pts received a median of 6 cycles cetuximab. RIT was tolerated well with only one °III mucositis/dysphagia. Overall response/remission rates were high (77,8%); 2-year estimate of local control was 80% hence reaching local control levels comparable to high-dose RT. Progression-free survival (PFS) at 2 years and median overall survival were only 62,5% and 22,2 mo respectively.

Conclusion

While local control and treatment response in RIT seems promising, PFS and overall survival are still hampered by distant failure. The potential benefit of RIT with cetuximab warrants exploration in a prospective controlled clinical trial.

Available only for authorised users

Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986,8(3):177-84. 10.1002/hed.2890080309CrossRefPubMed

Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW: Local-regional recurrence after surgery without postoperative irradiation for carciomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 2007, 67: 982-987.CrossRefPubMed

Gurney TA, Eisele DW, Weinberg V, Shin E, Lee N: Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope 2005,115(7):1278-82. 10.1097/01.MLG.0000165381.64157.ADCrossRefPubMed

Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Hinerman RW, Villaret DB: Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004,26(2):154-62. 10.1002/hed.10380CrossRefPubMed

Chen AM, Bucci MK, Weinberg V, Garcia J, Quivey JM, Schechter NR, Phillips TL, Fu KK, Eisele DW: Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 2006,66(1):152-9.CrossRefPubMed

Garden AS, Weber RS, Ang KK, Morrison WH, Matre J, Peters LJ: Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer 1994,73(10):2563-9. 10.1002/1097-0142(19940515)73:10<2563::AID-CNCR2820731018>3.0.CO;2-XCrossRefPubMed

Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK: Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 2006, 66: 1044-1050.CrossRefPubMed

Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van Den Ende PL, Burlage F: Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005, 61: 103-111.CrossRefPubMed

Schulz-Ertner D, Nikoghosyan A, Didinger B, Münter M, Jäkel O, Karger CP, Debus J: Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005,104(2):338-44. 10.1002/cncr.21158CrossRefPubMed

10.

Münter M, Umathum V, Nikoghosyan A, Jensen A, Hof H, Jaekel O, Debus J: Combination of intensity modulated radiation therapy (IMRT) and a carbon ion boost for subtotal resected or inoperable adenoid cystic carcinomas (ACC's) of the head and neck. PTCOG meeting 2009. abstract FC84

11.

Umathum V, Jensen A, Nikoghosyan A, Hof H, Jaekel O, Debus J, Münter MW: Intensitätsmodulierte Radiotherapie (IMRT) in Kombination mit einem Kohlenstoffionenbosst (C-12) bei adenoidzystischen Karzinomen (ACCs) der Kopf-/Halsregionen: Prognostischer Vergleich zwischen resezierten und nicht-resezierten Patienten. DEGRO meeting 2010. abstract W19-04. as of 30.06.2010 http://degro.wcenter.de/dav/html/kongress2010/eposter/W19-04.pdf abstract W19-04. as of 30.06.2010

12.

Huber PE, Debus J, Latz D, Zierhut D, Bischof M, Wannenmacher M, Engenhart-Cabillic R: Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam? Radiother Oncol 2001,59(2):161-7. 10.1016/S0167-8140(00)00273-5CrossRefPubMed

13.

Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE: Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 2003,129(9):944-8. 10.1001/archotol.129.9.944CrossRefPubMed

14.

Mizoe JE, Tsujii H, Kamada T, Matsuoka Y, Tsuji H, Osaka Y, Hasegawa A, Yamamoto N, Ebihara S, Konno A: Organizing Committee for the Working Group for Head-And-Neck Cancer. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004,60(2):358-64.CrossRefPubMed

15.

Haddad RI, Posner MR, Busse PM, Norris CM, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB: Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol 2006, 29: 153-157. 10.1097/01.coc.0000203756.36866.17CrossRefPubMed

16.

Airoldi M, Pedani F, Marchionatti S, Gabriele AM, Succo G, Gabriele P, Bumma C: Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma. Tumori 2001, 87: 14-17.PubMed

17.

Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A: Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 2009, 135: 687-692. 10.1001/archoto.2009.70CrossRefPubMed

18.

Pederson AW, Haraf DJ, Blair EA, Stenson KM, Witt ME, Vokes EE, Salama JK: Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol 2010, 95: 308-311. 10.1016/j.radonc.2010.03.006CrossRefPubMed

19.

Vered M, Braunstein E, Buchner A: Immunhistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002, 24: 632-636. 10.1002/hed.10104CrossRefPubMed

20.

Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN: Concomitant inhibition of epidermal growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma on an orthotopic nude mouse model. Mol Cancer Ther 2006, 5: 2696-2705. 10.1158/1535-7163.MCT-05-0228CrossRefPubMed

21.

De Haan LD, de Mulder PH, Vermorken JB, Schornagel JH, Vermey A, Verweij J: Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 1992, 14: 273-277. 10.1002/hed.2880140403CrossRefPubMed

22.

Creagan ET, Woods JE, Rubin J, Schaid DJ: Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer 1988, 62: 2313-2319. 10.1002/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4CrossRefPubMed

23.

Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM, Miller D: Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 1987, 60: 2869-2872. 10.1002/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-YCrossRefPubMed

24.

Venook AP, Tseng A, Meyers FJ, Silverberg I, Boles R, Fu KK, et al.: Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 1987, 5: 951-955.PubMed

25.

Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II Consortium Study. J Clin Oncol 2005, 23: 585-590. 10.1200/JCO.2005.06.125CrossRefPubMed

26.

Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, Liberatoscioli C, Quattrone P, Calderone RG, Rinaldi G, Pilotti S, Licitra L: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncology 2009, 45: 574-578. 10.1016/j.oraloncology.2008.07.010CrossRefPubMed

27.

Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL: Phase II study of lapatinib in recurrent or metastatic epidermal growth fator receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007, 25: 3978-3984. 10.1200/JCO.2007.11.8612CrossRefPubMed

28.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354: 567-578. 10.1056/NEJMoa053422CrossRefPubMed

29.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11: 21-28. 10.1016/S1470-2045(09)70311-0CrossRefPubMed

30.

Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, Hamoir M, Géry B, Julieron M, Castaing M, Bardet E, Grégoire V, Bourhis J: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008, 26: 5518-5523. 10.1200/JCO.2007.15.0102CrossRefPubMed

31.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92: 205-216. 10.1093/jnci/92.3.205CrossRefPubMed

32.

Curran D Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA: Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007, 25: 2191-2197. 10.1200/JCO.2006.08.8005CrossRefPubMed

33.

Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF, Barker FG, Adams JA, Lopes VV, Varvares M, Loeffler JS, Chan AW: Proton beam radiation therapy for skull base adenoid cystic carcinoma. Arch Otolaryngol Head Neck Surg 2006,132(11):1242-9. 10.1001/archotol.132.11.1242CrossRefPubMed

34.

Münter MW, Schulz-Ertner D, Hof H, Nikoghosyan A, Jensen A, Nill S, Huber P, Debus J: Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the treatment of incompletely and completely resected adenoid cystic carcinomas of the head and neck: initial clinical results and toxicity of treatment. Radiat Oncol 2006, 1: 17. 10.1186/1748-717X-1-17PubMedCentralCrossRefPubMed

35.

Gomez DR, Hoppe BS, Wolden SL, Zhung JE, Patel SG, Kraus DH, Shah JP, Ghossein RA, Lee NY: Outcomes and prognostic variables in adenoid cystic carcinoma of the head and neck: a recent experience. Int J Radiat Oncol Biol Phys 2008, 70: 1365-1372.CrossRefPubMed

36.

Lloyd S, Yu JB, Wilson LD, Decker RH: Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including analysis of adjuvant radiation therapy. Am J Clin Oncol 2010, in press.

37.

Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59: 1935-1940.PubMed

38.

Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ: Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother Radiopharm 1999, 14: 451-463. 10.1089/cbr.1999.14.451CrossRefPubMed

Title: RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab
Authors: Alexandra D Jensen
Jürgen Krauss
Wilko Weichert
Jürgen Debus
Marc W Münter
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2010
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-5-102

Keynote webinar | Spotlight on medication adherence

Springer Medicine

RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

Application of volumetric modulated arc therapy (VMAT) in a dual-vendor environment

Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size

Dosimetric comparison using different multileaf collimeters in intensity-modulated radiotherapy for upper thoracic esophageal cancer

Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer

Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy

3D-CT implanted interstitial brachytherapy for T2b nasopharyngeal carcinoma